0A4M Stock Chart & Stats
$85.46
$0.00(0.00%)
At close: 4:00 PM EDT
$85.46
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$56.00 - $85.46
Previous CloseN/A
Volume0.00
Average Volume (3M)3.00
Market Cap
$34.27B
Enterprise Value$25.72K
Total Cash (Recent Filing)$1.95B
Total Debt (Recent Filing)$1.40B
Price to Earnings (P/E)35.1
Beta0.64
Next Earnings
Oct 22, 2026EPS Estimate
0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.59
Shares Outstanding377,360,780
10 Day Avg. Volume0
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio0.67
Price to Book (P/B)9.43
Price to Sales (P/S)5.56
P/FCF Ratio24.04
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$93.24Price Target Upside9.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)2.67
Revenue Forecast (FY)$5.23B
Bulls Say, Bears Say
Bulls Say
Double-Digit Revenue Growth And Expanding CGM AccessDouble-digit quarterly growth, higher full-year guidance and broader reimbursement support indicate durable expansion in the addressable CGM market. Wider payer coverage can improve access for type 2 patients and support recurring sensor demand over the next several quarters.
Strong Margin Expansion And Operating LeverageThe 400-basis-point gross-margin improvement and higher operating margin show meaningful scale benefits as Dexcom grows. Management’s raised margin targets suggest profitability gains may persist, provided product launches and manufacturing investments remain well controlled.
Robust Cash Generation And Lower LeverageStrong cash conversion gives Dexcom resources to fund manufacturing capacity, product development and strategic initiatives without relying heavily on debt. Lower leverage further improves financial flexibility, although free-cash-flow growth has recently moderated.
Bears Say
Revenue Growth DecelerationA sustained slowdown would make future growth more dependent on new indications, reimbursement wins and product adoption. It could also limit additional operating leverage and reduce confidence that recent margin expansion will continue at the same pace.
Medicare Coverage Timing And ConditionsMedicare access could materially expand the eligible CGM population, but delayed timing or restrictive conditions would defer that opportunity. Uncertainty also complicates patient acquisition planning and leaves an important medium-term growth catalyst outside Dexcom’s control.
Manufacturing Ramp And Product Execution RiskNew Irish capacity should support long-term supply, but ramp costs can pressure margins before utilization improves. Any recurrence of quality or out-of-box failures could also increase warranty expense, disrupt customer experience and slow adoption.
Dexcom News
0A4M FAQ
What was Dexcom’s price range in the past 12 months?
Dexcom lowest share price was $56.00 and its highest was $85.46 in the past 12 months.
What is Dexcom’s market cap?
Dexcom’s market cap is $34.27B.
When is Dexcom’s upcoming earnings report date?
Dexcom’s upcoming earnings report date is Oct 22, 2026 which is in 52 days.
How were Dexcom’s earnings last quarter?
Dexcom released its earnings results on Jul 30, 2026. The company reported $0.7 earnings per share for the quarter, beating the consensus estimate of $0.611 by $0.089.
Is Dexcom overvalued?
According to Wall Street analysts Dexcom’s price is currently Undervalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate is 0.67.
How many shares outstanding does Dexcom have?
Dexcom has 377,360,780 shares outstanding.
What happened to Dexcom’s price movement after its last earnings report?
Dexcom reported an EPS of $0.7 in its last earnings report, beating expectations of $0.611. Following the earnings report the stock price went up 12.431%.
Which hedge fund is a major shareholder of Dexcom?
Currently, no hedge funds are holding shares in GB:0A4M
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dexcom Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$93.24 (9.10% Upside)
$93.24 (9.10% Upside)
Blogger Sentiment
Bullish
GB:0A4M Sentiment 66%
Sector Average 60%
Sector Average 60%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-17.52%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-11.90%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Dexcom
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
0A4M Company Deck
0A4M Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a broadly positive operational and financial message: double-digit revenue growth, substantial margin expansion (400 bps YoY), strong cash generation, successful product rollouts and encouraging clinical data (CONNECT) that is driving payer coverage momentum. Near-term headwinds include FX impact, Ireland manufacturing ramp costs, tougher international comps in the back half, and remaining uncertainties around Medicare coverage terms and timing. Overall, achievements and momentum on growth, margins, cash flow, product adoption and clinical evidence substantially outweigh the manageable near-term challenges.View all GB:0A4M earnings summaries0A4M Revenue Breakdown
71.53% U.S.
28.47% International
0A4M Stock 12 Month Forecast
Average Price Target
$93.24
▲(9.10% Upside)
Technical Analysis
Abbott Laboratories
―
Insulet
―
Medtronic
―
Tandem Diabetes Care
―
Senseonics Holdings
―